Chemomab Therapeutics Ltd.
CMMB · NASDAQ
Market closed$1.56$0.040000 (+2.63%)After hours $1.51 · -3.13%
Key statistics
Previous close$1.52
Open$1.50
Day high$1.58
Day low$1.50
52-week high$4.84
52-week low$1.35
Market cap9.60M
Volume91.95K
Average volume124.02K
P/E ratio-0.96
Forward P/E—
EPS-1.62
Dividend yield0.00%
Market context
Why it moved
CMMB shares edged higher amid modest buying interest, as no specific major catalyst was identified in today's available news, suggesting the uptick was likely driven by general market momentum and low-volume trading activity.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · July 16, 2026HBM boosts Chemomab Therapeutics Ltd. (CMMB) stake amid Scipher merger planPharmaceutical Executive · July 9, 2026Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing AgreementTradingView · July 8, 2026Chemomab Therapeutics: Merger creates an AI-powered precision medicine leader advancing nebokitug for RA with $30M fundingGlobeNewswire · July 8, 2026Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid ArthritisMoomoo · July 8, 2026Press Release: Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid ArthritisGlobeNewswire · March 19, 2026Chemomab Therapeutics Announces Year End and Fourth Quarter Mt Newswire · July 8, 2026Chemomab Therapeutics, Scipher Medicine to Merge in All-Stock Deal Benzinga · May 14, 2026Chemomab Therapeutics Q1 EPS $(0.24) Beats $(0.31) Estimate Benzinga · March 19, 2026Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate Benzinga · December 2, 2025Chemomab Therapeutics Data From Phase 2 SPRING Study Shows Nebokitug Was Safe, Well Tolerated In Participants With Primary Sclerosing Cholangitis At Up To 48 Weeks Of Treatment Benzinga · August 27, 2025Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25 Benzinga · August 19, 202512 Health Care Stocks Moving In Tuesday's After-Market Session